Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
종목 코드 AIMDW
회사 이름Ainos Inc
상장일Aug 08, 1996
CEOMr. Chun-Hsien Tsai
직원 수- -
유형Company Warrant
회계 연도 종료- -
주소8880 Rio San Diego Drive, Ste. 800
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92108
전화18588692986
웹사이트https://www.ainos.com/
종목 코드 AIMDW
상장일Aug 08, 1996
CEOMr. Chun-Hsien Tsai
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음